Citizens Rates NRC Health (NRC) buy, $23 Price Target
Citizens has reiterated its buy rating on NRC, maintaining a positive outlook with a $23 price target, a 18.84% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Citizens rated NRC Health ($NRC) "buy" with a $23 price target on June 22, 2026.
Since the rating, $NRC is up 11.9% after 1 week, up 11.6% after 1 month and up 5.0% to date (from the $19.19 close on Jun 22, 2026).
NRC
NRC Health
Key Points
- Citizens analyst Constantine Davides reiterated a buy rating on NRC with a price target of $23 on June 22, 2026.
- Citizens's $23 price target implies 18.84% upside from NRC Health's ($NRC) current $19.35 share price.
- NRC shares were trading at $19.35 on Monday, reflecting interest from various institutional investors.
- Insiders at NRC have been actively buying shares, with notable purchases by executives in early 2026.
Get $NRC trade alerts by text
We text you when insiders, Congress or big funds trade $NRC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated NRC Health alert may contain errors. Disclosures
Citizens analyst Constantine Davides has reiterated a buy rating on NRC, setting a price target of $23. This announcement was made on June 22, 2026, highlighting a positive outlook for the company. NRC shares were trading at $19.35 on Monday.
Other Institutional Activity in NRC
Kayne Anderson Rudnick Investment Management LLC reduced its holdings by 21,473 shares, leaving it with 2,636,355 shares valued at approximately $44.8 million. Morgan Stanley also trimmed its position by 1,829 shares, ending with 1,001,880 shares worth about $17 million. BlackRock, Inc. decreased its stake by 29,468 shares, holding 975,855 shares valued at $16.6 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 662,837 shares, valued at roughly $11.3 million. Geode Capital Management, LLC increased its stake by 10,336 shares, bringing its total to 393,847 shares worth about $6.7 million.
NRC Health Stock Down 5.9%
Shares of NRC traded near $19.35 on Monday. The company's stock has seen various institutional movements, reflecting ongoing interest. The 52-week range for NRC is not available, but the current trading price suggests a focus on the company's future potential.
$NRC price target
NRC Health daily closes and this analyst's $23 target. Not advice.
Insider Buying and Selling at NRC Health
Insider activity at NRC has been notable with several executives buying shares. On March 12, 2026, Jason Russell Rau, Executive Vice President, purchased 60,000 shares. Shane Harrison, EVP & Chief Financial Officer, bought 8,000 shares at an average price of $12.27 on February 17, 2026. Additionally, Parul Bhandari and Stephen Lockhart each acquired 8,819 shares on January 22, 2026.
Analysts Set New Price Targets
On June 22, 2026, Citizens initiated a buy rating on NRC with a price target of $23, affirming confidence in the company's potential.
Bottom Line
The reiteration of a buy rating by Citizens, coupled with insider purchases, suggests optimism around NRC's future prospects. Institutional activities indicate varied interest levels, with some funds reducing and others increasing their positions. As always, it's important to remember that analyst ratings are projections and investors should consider their own research and risk tolerance.
Related Filing Alerts
Source: Citizens's rating change on $NRC (Jun 22, 2026). Written by software, not financial advice. How we make alerts